Galactin-3: diagnostic and prognostic value in patients with chronic heart failure

Now there is a relevant development of the new biomarkers capable to serve as the instrument of early diagnostics of a disease for the purpose of selection of a pharmacotherapy and further monitoring of its efficiency. Galektin-3 is the atypical representative of the family of galektin. Its particip...

Full description

Bibliographic Details
Main Authors: A M Aliyeva, I E Baykova, V A Kislyakov, E T Gasanova, I I Almazova, T V Pinchuk, Yu N Fedulayev, I V Zhbanov, V A Perevertov, I V Kovtyukh, I G Nikitin, E V Reznik
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2019-09-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/33682/pdf
Description
Summary:Now there is a relevant development of the new biomarkers capable to serve as the instrument of early diagnostics of a disease for the purpose of selection of a pharmacotherapy and further monitoring of its efficiency. Galektin-3 is the atypical representative of the family of galektin. Its participation in fibrosis, remodeling of heart, the immunologic answer and inflammatory reactions are shown. Prognostic value is discussed and diagnostic opportunities of Galektin-3 at CHF are widely studied and take root into clinical practice. Now a great deal of research devoted to the studying of Galektin-3, possibilities of its use as a biomarker at diagnostics, forecasting of outcomes and the choice of therapeutic strategy at other cardiovascular diseases has been conducted.
ISSN:0040-3660
2309-5342